Behavioral
Children's Health System of Texas
Children's Health System of Texas was paid $263.77M by Medicaid between Jan 2018 and Dec 2024, across 387 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoCHILDREN'S HEALTH SYSTEM OF TEXAS
DALLAS, TX 75235
DALLAS, TX 75235
33aNPI1194743013assigned 07/18/2006
33bProvider typeBehavioral Analyst
28Total paid$263.77M
24GClaims1,364,671
24DCodes billed387
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Behavioral Analyst providers in Texas
Rank by total paid#1 of 53
Median peer was paid$373K
This provider vs. median708×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,891 | $209K | |
| 2019 | 8,654 | $2.14M | |
| 2020 | 62,709 | $10.42M | |
| 2021 | 379,126 | $74.88M | |
| 2022 | 370,303 | $66.85M | |
| 2023 | 339,116 | $68.53M | |
| 2024incomplete | 202,872 | $40.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 120,240 | 117,061 | $53.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 41,368 | 40,585 | $37.37M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.2% | 193,728 | 185,835 | $11.16M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 40,917 | 40,374 | $10.59M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 3.6% | 3,902 | 3,837 | $9.55M |
| 95782 | 3.6% | 2,671 | 2,604 | $9.47M | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 10,964 | 10,589 | $8.68M |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 2.9% | 2,335 | 1,090 | $7.73M |
| A0425 | Ground mileage, per statute mile | 2.6% | 8,926 | 8,515 | $6.75M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 57,348 | 55,359 | $4.54M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.7% | 1,438 | 1,419 | $4.40M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.5% | 2,230 | 2,201 | $3.93M |
375 more codes
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.4% | 328 | $3.67M |
| A0433 | Advanced life support, level 2 (als 2) | 1.4% | 2,715 | $3.67M |
| 95812 | 1.3% | 3,343 | $3.46M | |
| A0427 | Emergency ambulance ride, advanced life support | 1.3% | 3,325 | $3.44M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.3% | 1,631 | $3.37M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.3% | 42,197 | $3.31M |
| J2357 | Injection, omalizumab, 5 mg | 1.1% | 666 | $2.99M |
| 92579 | 1.0% | 11,601 | $2.72M | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 4,221 | $2.29M |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 28,542 | $2.22M |
| 92567 | <1% | 23,665 | $2.19M | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 13,048 | $2.16M |
| 67311 | <1% | 702 | $2.14M | |
| 95811 | <1% | 622 | $1.73M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,713 | $1.63M |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,889 | $1.57M |
| 76770 | <1% | 5,485 | $1.51M | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,967 | $1.41M |
| 94010 | <1% | 6,424 | $1.36M | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 17,089 | $1.32M |
| 92587 | <1% | 6,119 | $1.22M | |
| 85027 | <1% | 22,136 | $1.21M | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 19,359 | $1.11M |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,761 | $1.10M |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 913 | $1.01M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,813 | $1.01M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 6,483 | $960K |
| 80069 | <1% | 7,900 | $943K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 891 | $898K |
| 80053 | Comprehensive metabolic panel | <1% | 11,368 | $863K |
| 93226 | <1% | 1,691 | $817K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,379 | $815K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,836 | $788K |
| 87428 | <1% | 9,494 | $786K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,247 | $693K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,671 | $675K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 5,412 | $664K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,308 | $653K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 8,555 | $651K |
| 36430 | <1% | 1,186 | $625K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 604 | $615K |
| 84439 | <1% | 13,265 | $597K | |
| 87799 | <1% | 2,254 | $594K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,003 | $579K |
| 97803 | <1% | 12,382 | $573K | |
| 93325 | <1% | 1,251 | $565K | |
| 82977 | <1% | 9,955 | $551K | |
| 86902 | <1% | 1,633 | $549K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,340 | $504K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,992 | $499K |
| 80061 | Lipid panel | <1% | 3,846 | $498K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 327 | $461K |
| 74018 | <1% | 3,348 | $455K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,463 | $454K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 198 | $449K |
| 81003 | <1% | 22,192 | $446K | |
| 92557 | <1% | 1,708 | $430K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 3,003 | $428K |
| 73140 | <1% | 2,290 | $426K | |
| 85045 | <1% | 12,427 | $423K | |
| 80076 | <1% | 4,728 | $411K | |
| 85007 | <1% | 18,330 | $389K | |
| 81001 | <1% | 10,600 | $372K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 361 | $364K |
| 84460 | <1% | 7,988 | $362K | |
| 93320 | <1% | 635 | $357K | |
| 82948 | <1% | 11,663 | $349K | |
| 82728 | <1% | 6,500 | $342K | |
| 92652 | <1% | 231 | $323K | |
| 80197 | <1% | 2,196 | $320K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,003 | $320K |
| 97802 | <1% | 4,114 | $317K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,708 | $316K |
| 54161 | <1% | 109 | $308K | |
| 92582 | <1% | 1,048 | $284K | |
| 87070 | <1% | 3,836 | $282K | |
| 92550 | <1% | 4,004 | $275K | |
| 83735 | <1% | 9,238 | $267K | |
| 87497 | <1% | 1,743 | $267K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,771 | $264K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 1,609 | $252K |
| 86850 | <1% | 2,231 | $245K | |
| 74019 | <1% | 1,475 | $244K | |
| 84100 | <1% | 6,295 | $243K | |
| 92552 | <1% | 2,163 | $232K | |
| 54150 | <1% | 366 | $226K | |
| A0436 | Rotary wing air mileage, per statute mile | <1% | 33 | $225K |
| 29075 | <1% | 900 | $216K | |
| 84703 | <1% | 3,707 | $216K | |
| 96167 | <1% | 1,422 | $216K | |
| 82248 | <1% | 5,860 | $212K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,261 | $201K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,128 | $199K |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | <1% | 32 | $196K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,016 | $192K |
| 97165 | <1% | 888 | $190K | |
| 77080 | <1% | 777 | $188K | |
| 92555 | <1% | 3,755 | $185K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,268 | $181K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 632 | $177K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 259 | $173K |
| 36415 | Collection of venous blood by venipuncture | <1% | 98,871 | $170K |
| 82247 | <1% | 4,298 | $164K | |
| 73090 | <1% | 1,275 | $163K | |
| 85610 | <1% | 3,103 | $160K | |
| 29065 | <1% | 415 | $159K | |
| 82610 | <1% | 3,630 | $158K | |
| 96156 | <1% | 1,382 | $153K | |
| 82784 | <1% | 1,701 | $151K | |
| 87040 | <1% | 2,097 | $145K | |
| 82565 | <1% | 3,244 | $137K | |
| 95117 | <1% | 2,503 | $137K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 1,120 | $135K |
| 86140 | <1% | 5,004 | $134K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 613 | $133K |
| 82803 | <1% | 1,411 | $132K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,190 | $131K |
| 83880 | <1% | 980 | $130K | |
| 73610 | <1% | 965 | $130K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,073 | $125K |
| V5266 | Battery for use in hearing device | <1% | 1,011 | $124K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,024 | $123K |
| 73130 | <1% | 1,016 | $123K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,099 | $112K |
| 86900 | <1% | 2,311 | $109K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 41 | $106K |
| 95715 | <1% | 46 | $105K | |
| 84450 | <1% | 3,537 | $104K | |
| V5275 | Ear impression, each | <1% | 580 | $102K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 560 | $101K |
| 86923 | <1% | 829 | $100K | |
| 77072 | <1% | 360 | $98K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,460 | $95K |
| 73070 | <1% | 990 | $94K | |
| 86901 | <1% | 2,311 | $91K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,448 | $87K |
| 78725 | <1% | 89 | $86K | |
| 83021 | <1% | 1,136 | $85K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,013 | $84K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 16,957 | $81K |
| 96158 | <1% | 602 | $77K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 545 | $77K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,732 | $73K |
| 64642 | <1% | 155 | $73K | |
| 95115 | <1% | 1,856 | $72K | |
| 84145 | <1% | 2,422 | $72K | |
| 73110 | <1% | 638 | $71K | |
| 97161 | <1% | 482 | $71K | |
| 81025 | <1% | 1,808 | $71K | |
| 92556 | <1% | 800 | $69K | |
| 83550 | <1% | 1,239 | $67K | |
| 76857 | <1% | 395 | $67K | |
| 92626 | <1% | 254 | $66K | |
| 87102 | <1% | 350 | $65K | |
| 80050 | General health panel | <1% | 581 | $65K |
| 93296 | <1% | 725 | $63K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,418 | $63K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 11,916 | $60K |
| 83615 | <1% | 1,172 | $60K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 778 | $59K |
| 86003 | <1% | 1,056 | $59K | |
| 90837 | Psychotherapy session, about an hour | <1% | 171 | $58K |
| 64643 | <1% | 147 | $55K | |
| 73080 | <1% | 212 | $54K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 945 | $53K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 587 | $53K |
| 95712 | <1% | 39 | $52K | |
| 92526 | <1% | 439 | $51K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 607 | $50K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 15 | $49K |
| 96376 | <1% | 1,230 | $49K | |
| 82947 | <1% | 1,731 | $48K | |
| 73100 | <1% | 261 | $48K | |
| 82040 | <1% | 934 | $47K | |
| 31575 | <1% | 218 | $47K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,163 | $46K |
| 44970 | <1% | 12 | $45K | |
| 82570 | <1% | 1,006 | $45K | |
| 87077 | <1% | 774 | $43K | |
| 73564 | <1% | 138 | $42K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 29 | $41K |
| 85652 | <1% | 1,947 | $41K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 115 | $40K |
| 92593 | <1% | 232 | $40K | |
| 82010 | <1% | 645 | $40K | |
| 73590 | <1% | 359 | $39K | |
| 84403 | <1% | 369 | $39K | |
| 83540 | <1% | 870 | $39K | |
| 83690 | <1% | 1,259 | $38K | |
| 83001 | <1% | 497 | $38K | |
| 93786 | <1% | 192 | $37K | |
| 96409 | <1% | 140 | $37K | |
| 95076 | <1% | 83 | $35K | |
| 86803 | <1% | 664 | $35K | |
| 83970 | <1% | 217 | $35K | |
| V5010 | Assessment for hearing aid | <1% | 91 | $35K |
| 93225 | <1% | 73 | $34K | |
| 82627 | <1% | 325 | $33K | |
| 77081 | <1% | 311 | $33K | |
| 83002 | <1% | 418 | $32K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 135 | $32K |
| 85660 | <1% | 1,471 | $32K | |
| 95700 | <1% | 79 | $32K | |
| 94060 | <1% | 88 | $31K | |
| 70360 | <1% | 244 | $31K | |
| 31622 | <1% | 26 | $31K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 300 | $31K |
| 87535 | <1% | 51 | $31K | |
| 31231 | <1% | 175 | $31K | |
| 85240 | <1% | 205 | $30K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,487 | $30K |
| 87186 | <1% | 487 | $30K | |
| 85246 | <1% | 115 | $30K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,350 | $29K |
| 82043 | <1% | 657 | $29K | |
| 84156 | <1% | 562 | $27K | |
| J0586 | Injection, abobotulinumtoxina, 5 units | <1% | 16 | $26K |
| 83498 | <1% | 188 | $26K | |
| 84146 | <1% | 305 | $24K | |
| 99243 | <1% | 311 | $24K | |
| 96168 | <1% | 185 | $24K | |
| A0434 | Specialty care transport (sct) | <1% | 12 | $23K |
| 85730 | <1% | 718 | $23K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 695 | $23K |
| 93243 | <1% | 89 | $22K | |
| 92523 | <1% | 87 | $21K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 126 | $21K |
| 84520 | <1% | 549 | $20K | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 115 | $19K |
| 90378 | <1% | 904 | $19K | |
| 78350 | <1% | 83 | $18K | |
| 69210 | <1% | 120 | $18K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 842 | $17K |
| 80349 | <1% | 224 | $17K | |
| 96137 | <1% | 26 | $17K | |
| 96450 | <1% | 36 | $17K | |
| 85397 | <1% | 56 | $17K | |
| 76376 | <1% | 73 | $17K | |
| 83516 | <1% | 301 | $16K | |
| 84305 | <1% | 278 | $15K | |
| 92133 | <1% | 170 | $15K | |
| 73630 | <1% | 158 | $15K | |
| 87220 | <1% | 240 | $15K | |
| 80051 | <1% | 125 | $15K | |
| 87147 | <1% | 106 | $12K | |
| 84702 | <1% | 146 | $12K | |
| 72170 | <1% | 155 | $12K | |
| L8613 | Ossicula implant | <1% | 448 | $12K |
| 80143 | <1% | 274 | $11K | |
| 88304 | <1% | 93 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 230 | $11K |
| 86480 | <1% | 194 | $11K | |
| 80179 | <1% | 240 | $10K | |
| 87340 | <1% | 136 | $10K | |
| 77075 | <1% | 27 | $9K | |
| 86592 | <1% | 955 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 139 | $9K |
| 92610 | <1% | 49 | $8K | |
| 84075 | <1% | 287 | $8K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 21 | $8K |
| 86160 | <1% | 53 | $7K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 95 | $7K |
| 92083 | <1% | 46 | $7K | |
| 82330 | <1% | 199 | $7K | |
| 51798 | <1% | 94 | $7K | |
| 82088 | <1% | 53 | $6K | |
| 73560 | <1% | 49 | $6K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 88 | $6K |
| 90474 | <1% | 961 | $6K | |
| 92622 | <1% | 28 | $5K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 82 | $5K |
| 82657 | <1% | 37 | $5K | |
| 82785 | <1% | 79 | $5K | |
| 88108 | <1% | 62 | $5K | |
| 84132 | <1% | 194 | $5K | |
| P9011 | Blood, split unit | <1% | 13 | $5K |
| 87507 | <1% | 12 | $5K | |
| 80320 | <1% | 138 | $5K | |
| 51600 | <1% | 24 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 59 | $4K |
| 84244 | <1% | 51 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 55 | $4K |
| 92250 | <1% | 25 | $4K | |
| 87536 | <1% | 25 | $4K | |
| 89051 | <1% | 62 | $4K | |
| 43762 | <1% | 13 | $4K | |
| 82550 | <1% | 77 | $4K | |
| V5160 | Dispensing fee, binaural | <1% | 12 | $4K |
| 76536 | <1% | 13 | $4K | |
| 85055 | <1% | 72 | $4K | |
| A9554 | Iodine i-125 sodium iothalamate, diagnostic, per study dose, up to 10 microcuries | <1% | 111 | $4K |
| 12011 | <1% | 16 | $4K | |
| 96159 | <1% | 46 | $3K | |
| 76499 | <1% | 25 | $3K | |
| 29125 | <1% | 26 | $3K | |
| 84478 | <1% | 102 | $3K | |
| A0422 | Ambulance (als or bls) oxygen and oxygen supplies, life sustaining situation | <1% | 120 | $3K |
| 94728 | <1% | 12 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 43 | $3K |
| 96136 | <1% | 24 | $3K | |
| 84295 | <1% | 137 | $3K | |
| 85046 | <1% | 47 | $3K | |
| T2101 | Human breast milk processing, storage and distribution only | <1% | 704 | $3K |
| 86039 | <1% | 27 | $3K | |
| 82104 | <1% | 43 | $2K | |
| 92002 | <1% | 45 | $2K | |
| 72040 | <1% | 27 | $2K | |
| 73552 | <1% | 27 | $2K | |
| 95873 | <1% | 31 | $2K | |
| 96116 | <1% | 17 | $2K | |
| 84402 | <1% | 24 | $2K | |
| 95874 | <1% | 39 | $2K | |
| 82465 | <1% | 114 | $2K | |
| 73000 | <1% | 17 | $2K | |
| 17110 | <1% | 12 | $2K | |
| 83519 | <1% | 26 | $2K | |
| 92551 | <1% | 44 | $2K | |
| 73562 | <1% | 14 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,906 | $2K |
| 88184 | <1% | 28 | $2K | |
| 97162 | <1% | 15 | $2K | |
| 82390 | <1% | 28 | $2K | |
| 83520 | <1% | 30 | $2K | |
| 85018 | <1% | 130 | $2K | |
| 86706 | <1% | 27 | $2K | |
| 29130 | <1% | 13 | $2K | |
| 86376 | <1% | 44 | $2K | |
| 97016 | <1% | 27 | $1K | |
| 86704 | <1% | 28 | $1K | |
| 83605 | <1% | 29 | $1K | |
| 83695 | <1% | 31 | $1K | |
| 86708 | <1% | 15 | $1K | |
| 83655 | <1% | 41 | $1K | |
| 84484 | <1% | 29 | $1K | |
| 98960 | <1% | 93 | $1K | |
| 76937 | <1% | 14 | $1K | |
| 82310 | <1% | 27 | $1K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 151 | $1K |
| 88185 | <1% | 28 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 484 | $962.78 |
| 86709 | <1% | 15 | $953.80 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 27 | $870.69 |
| 86985 | <1% | 12 | $865.20 | |
| 82435 | <1% | 55 | $838.77 | |
| 87210 | <1% | 15 | $781.38 | |
| 83525 | <1% | 13 | $740.67 | |
| 97804 | <1% | 12 | $735.63 | |
| 80177 | <1% | 12 | $600.41 | |
| 86800 | <1% | 15 | $573.23 | |
| A4364 | Adhesive, liquid or equal, any type, per oz | <1% | 12 | $521.31 |
| 82150 | <1% | 15 | $521.10 | |
| 87808 | <1% | 15 | $439.45 | |
| A4565 | Slings | <1% | 134 | $366.60 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 14 | $300.87 |
| 90785 | <1% | 43 | $232.72 | |
| 90686 | <1% | 8,312 | $154.53 | |
| S8451 | Splint, prefabricated, wrist or ankle | <1% | 28 | $100.38 |
| 36416 | <1% | 215 | $41.52 | |
| 90656 | <1% | 921 | $23.12 | |
| 90680 | <1% | 1,030 | $0.01 | |
| 90670 | 0% | 2,382 | $0.00 | |
| 90633 | 0% | 913 | $0.00 | |
| 90707 | 0% | 153 | $0.00 | |
| 90648 | 0% | 1,161 | $0.00 | |
| 90700 | 0% | 301 | $0.00 | |
| 90710 | 0% | 90 | $0.00 | |
| 90734 | 0% | 44 | $0.00 | |
| 90677 | 0% | 389 | $0.00 | |
| 90723 | 0% | 657 | $0.00 | |
| 90716 | 0% | 141 | $0.00 | |
| 90381 | 0% | 35 | $0.00 | |
| 90698 | 0% | 175 | $0.00 | |
| 90697 | 0% | 127 | $0.00 | |
| 90696 | 0% | 90 | $0.00 | |
| 90620 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRIES, ROBERT (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Children's Health System of Texas | Plano, TX | $65.83M |
| Children's Health System of Texas | Dallas, TX | $1.51M |
| Pediatric Imaging Associates LLC | Plano, TX | $1.21M |
| Children's Health System of Texas | Dallas, TX | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.